Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity.

Clofarabine is a second generation of purine nucleoside analogues designed to combine the most favorable pharmacokinetic properties of fludarabine and cladribine. Clofarabine acts by inhibiting DNA polymerases and ribonucleotide reductase as well as by inducing apoptosis in cycling and non-cycling cells. Phase I/II clinical studies revealed its efficacy in hematological ...
malignancies, and in 2004 clofarabine was approved by the United States Food and Drug Administration for the treatment of pediatric relapsed or refractory acute lymphoblastic leukemia after at least two prior chemotherapy regimens. The mechanism of action, pharmacology and clinical activity of clofarabine is the subject of this review.
Mesh Terms:
Adenine Nucleotides, Animals, Antineoplastic Agents, Arabinonucleosides, Clinical Trials as Topic, Hematologic Neoplasms, Humans, Nucleosides
Mini Rev Med Chem
Date: Jun. 01, 2009
Download Curated Data For This Publication
177447
Switch View:
  • Chemical Interactions 4